Search results
Results from the WOW.Com Content Network
An established INN is known as a recommended INN (rINN), while a name that is still being considered is called a proposed INN (pINN). [ 3 ] National nonproprietary names such as British Approved Names (BAN), Dénominations Communes Françaises (DCF), Japanese Adopted Names (JAN) and United States Adopted Names (USAN) are nowadays, with rare ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
The International Nonproprietary Name (INN) tenamfetamine was recommended by the World Health Organization (WHO) in 1986. [39] It was recommended in the same published list in which the INN of 2,5-dimethoxy-4-bromoamphetamine (DOB), brolamfetamine, was recommended. [39]
Sacituzumab govitecan was added to the proposed International nonproprietary name (INN) list in 2015, [26] and to the recommended list in 2016. [27] Sacituzumab govitecan-hziy was approved for medical use in the United States in April 2020. [12] [13] [14] [28] [11]
The INN Tooltip International Nonproprietary Name of DOB, brolamfetamine, was proposed and recommended by the World Health Organization in 1986. [10] [11] It was registered with the organization as a supposed "anorexic" (appetite suppressant). [12]
Neluxicapone (INN Tooltip International Nonproprietary Name) is a catechol O-methyltransferase (COMT) inhibitor which has not been marketed as of 2024. [1] [2] [3] The drug is a nitrocatechol and is structurally related to other catechol COMT inhibitors like entacapone, tolcapone, and nebicapone.
Camrelizumab (SHR-1210) (INN [1]) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma. [2] This drug is being developed by Jiangsu HengRui Medicine Co., Ltd. As of 2019, camrelizumab is undergoing Phase II/III trials.
The INN name is "simeticone", which was added to the INN recommended list in 1999. [ 17 ] Simeticone is marketed under many brand names and in many combination drugs ; it is also marketed as a veterinary drug.